Worldwide Innovative Network Consortium: Building a Common Global Cancer Database
Posted: Friday, August 14, 2026
Worldwide Innovative Network Consortium: Building a Common Global Cancer Database
August 13, 2026
JCO Global Oncology 12:e2500720
DOI https://doi.org/10.1200/GO-25-00720
© 2026 by American Society of
Clinical Oncology
ABSTRACT
This review shares the ongoing work of the global Worldwide Innovative Network (WIN) Consortium for Precision Medicine to synthesize emerging cancer treatment data and to define the requirements for a common global cancer database that can truly support precision oncology. We performed a narrative review of emerging cancer treatment data, molecular profiling technologies, and existing clinicogenomic databases, focusing on how tumors are characterized, how subgroups are defined, and how demographic, lifestyle, and environmental factors are captured. The growth in molecular profiling technologies and the development of new targeted therapies are transforming cancer care. Tumors, regardless of tissue origin, are increasingly defined as composites of multiple, often rare, subgroups, each with distinct biology and likely response to specific therapies, based on multidimensional profiling of the tumor and its microenvironment. The solution lies in building vast databases that capture racial and ethnic diversity, reflected in genomic data, as well as diet and lifestyle factors that may have epigenetic impact on gene expression and post-translational modifications. A truly inclusive and informative data set must reflect global diversity, and there are multiple examples of demography-dependent differences in genomic signals. With members caring for and studying patients with cancer across five continents, WIN is actively exploring pathways to create a global cancer database, rich in clinical and molecular detail, granular enough for precise analysis, and large enough to power artificial intelligence–driven insights, provided appropriate data quality, validation, and governance frameworks are in place. This review surveys the current landscape and outlines practical paths forward to achieve this goal.
INTRODUCTION
Cancer remains a leading global health challenge, with millions of new cases diagnosed annually. Despite advances, its molecular complexity, heterogeneity, and variable treatment responses demand continuous research and innovation. Traditional cytotoxic therapies adopt a one-size-fits-all approach that overlooks tumor molecular diversity, the microenvironment, and host immunity, yielding suboptimal outcomes and highlighting the need for personalized strategies.
Precision oncology (PO) offers a transformative approach by tailoring treatment to the molecular, immunologic, and microenvironmental characteristics of tumors. As cancers are increasingly recognized as collections of distinct and often rare subtypes, such as identifying patients' subsets whose tumors bear specific key prognostic and predictive biomarkers requires large, diverse, multi-institutional cohorts. However, limited access to such data sets remains a key barrier to clinical implementation and translational research. Although the use of targeted therapies, including immune-based treatments and antibody-drug conjugates, is expanding rapidly, their efficacy in early-phase trials is often restricted to narrowly defined molecular subgroups available in current databases, which results in limited ultimate access due to narrow regulatory approvals.
Overcoming these challenges requires a global infrastructure capable of integrating and analyzing large-scale, multi-dimensional data sets from diverse populations. Whether centralized or federated, it should harmonize demographic, molecular, and clinical outcome data, alongside key likely modifiers such as geographic origin, ethnicity, diet, smoking status, and environmental exposures, while ensuring confidentiality and data privacy remain paramount.
A major limitation of current cancer data sets is their lack of diversity, with underrepresentation of individuals of non-European ancestry. This restricts discovery of actionable mutations, and the implications of different genetic contexts, likely biases biomarker validation, and limits generalizability. As a result, therapies based on European-centric data may show different efficacy or unexpected toxicity in other populations. Developing globally representative databases could advance research and clinical translation by supporting artificial intelligence (AI)–driven trial design and real-world evidence (RWE) generation, and accelerating equitable, personalized treatments. Global efforts such as the World Economic Forum and the Global Alliance for Genomics and Health (GA4GH) highlight the urgency of inclusive, collaborative frameworks for advancing PO.
View the full article here: Download pdf